Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34(+) cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34(+) cells

The yield of CD34(+) PBPC and colony-forming units-granulocyte-macrophage ( CFU-GM) in leukapheresis products and the expression of the adhesion molecu les CD11a, CD31, CD49d, CD49e, CD54, CD58, CD62L, c-kit (CD117), Thy-1 (CD9 0, CD33, CD38, and HLA-DR on CD34(+) PBPC were analyzed in patients with ca ncer of the testis (n = 10), breast cancer (n = 10), Hodgkin's disease (n = 20), high-grade (n = 20) and low-grade (n = 20) non-Hodgkin's lymphoma, an d healthy donors (n = 20) undergoing G-CSF (filgrastim)-stimulated PBPC mob ilization. For each disease entity, G-CSF was administered in two different doses, 10 mu g 6-CSF/kg body weight (BW)/day s.c. vs. 24 mu g G-CSF/kg BW s.c./day in steady-state condition. Data were compared for each dose group separately. Patients with cancer of the testis and breast cancer mobilized significantly more CD34(+) cells than patients with high-grade and low-grad e non-Hodgkin's lymphoma and Hodgkin's disease (p < 0.05). Correspondingly, expression of CD49d an CD34(+) PBPC was significantly lower in the same pa tients with cancer of the testis compared with high-grade and low-grade non -Hodgkin's lymphoma and Hodgkins' disease and in patients with breast cance r compared with high-grade and low-grade non-Hodgkin's lymphoma, Hodgkins's disease, and healthy donors. Similar results were obtained for CD49e. Thes e data suggest that the expression of the adhesion molecules CD49d and CD49 e on G-CSF-mobilized CD34(+) cells of patients with solid tumors, non-Hodgk in's lymphoma, Hodgkin's disease, and healthy donors is inversely correlate d with the amount of mobilized CD34(+) cells.